| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 80 | 2026 | 682 | 12.690 |
Why?
|
| Neoplastic Stem Cells | 51 | 2025 | 412 | 11.420 |
Why?
|
| Leukemia | 24 | 2025 | 245 | 5.200 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 19 | 2025 | 279 | 4.420 |
Why?
|
| Sesquiterpenes | 25 | 2024 | 52 | 3.710 |
Why?
|
| Hematopoietic Stem Cells | 43 | 2024 | 420 | 3.590 |
Why?
|
| Sulfonamides | 19 | 2025 | 580 | 3.530 |
Why?
|
| Antineoplastic Agents | 34 | 2025 | 2194 | 2.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2025 | 1953 | 2.350 |
Why?
|
| Azacitidine | 14 | 2025 | 156 | 1.970 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2025 | 881 | 1.590 |
Why?
|
| Myelodysplastic Syndromes | 10 | 2024 | 147 | 1.450 |
Why?
|
| Leukemia, Myeloid | 9 | 2011 | 48 | 1.410 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 8 | 2025 | 127 | 1.410 |
Why?
|
| Oxidative Phosphorylation | 8 | 2024 | 210 | 1.410 |
Why?
|
| Drug Delivery Systems | 4 | 2019 | 380 | 1.310 |
Why?
|
| Cell Self Renewal | 3 | 2022 | 53 | 1.310 |
Why?
|
| Stem Cells | 11 | 2020 | 626 | 1.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2019 | 240 | 1.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 9 | 2016 | 56 | 1.140 |
Why?
|
| Mice | 74 | 2026 | 18339 | 1.050 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2025 | 969 | 1.020 |
Why?
|
| Animals | 95 | 2026 | 38058 | 0.980 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2018 | 339 | 0.950 |
Why?
|
| Cell Line, Tumor | 32 | 2026 | 3540 | 0.930 |
Why?
|
| Humans | 166 | 2026 | 144759 | 0.900 |
Why?
|
| NF-kappa B | 15 | 2024 | 661 | 0.900 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2024 | 167 | 0.870 |
Why?
|
| Blast Crisis | 8 | 2025 | 35 | 0.850 |
Why?
|
| Apoptosis | 23 | 2024 | 2430 | 0.830 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 338 | 0.820 |
Why?
|
| Mitochondria | 5 | 2026 | 984 | 0.800 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2022 | 47 | 0.770 |
Why?
|
| Tumor Cells, Cultured | 18 | 2022 | 919 | 0.740 |
Why?
|
| Electron Transport Complex II | 2 | 2019 | 28 | 0.740 |
Why?
|
| Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.720 |
Why?
|
| Cytarabine | 5 | 2019 | 66 | 0.700 |
Why?
|
| Signal Transduction | 18 | 2025 | 5226 | 0.700 |
Why?
|
| Antigens, CD34 | 12 | 2023 | 88 | 0.690 |
Why?
|
| Mice, Inbred NOD | 17 | 2020 | 610 | 0.690 |
Why?
|
| Fatty Acids | 3 | 2020 | 450 | 0.680 |
Why?
|
| Neoplasm Proteins | 7 | 2016 | 442 | 0.680 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2018 | 293 | 0.660 |
Why?
|
| Cell Survival | 19 | 2022 | 1098 | 0.650 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2020 | 190 | 0.640 |
Why?
|
| Mice, SCID | 16 | 2020 | 369 | 0.630 |
Why?
|
| STAT3 Transcription Factor | 1 | 2022 | 207 | 0.630 |
Why?
|
| Lipase | 1 | 2020 | 75 | 0.630 |
Why?
|
| Aldehyde Dehydrogenase | 3 | 2017 | 99 | 0.620 |
Why?
|
| Cell Proliferation | 17 | 2024 | 2496 | 0.610 |
Why?
|
| Flow Cytometry | 14 | 2020 | 1173 | 0.600 |
Why?
|
| Leukopoiesis | 1 | 2019 | 11 | 0.590 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2019 | 17 | 0.590 |
Why?
|
| NADPH Oxidase 2 | 1 | 2019 | 35 | 0.590 |
Why?
|
| Glutathione | 4 | 2019 | 375 | 0.580 |
Why?
|
| Succinate Dehydrogenase | 4 | 2026 | 57 | 0.570 |
Why?
|
| Calcium | 1 | 2024 | 1183 | 0.560 |
Why?
|
| Amino Acids | 2 | 2020 | 521 | 0.550 |
Why?
|
| Gene Expression Profiling | 7 | 2024 | 1782 | 0.550 |
Why?
|
| Cysteine | 1 | 2019 | 210 | 0.540 |
Why?
|
| Hematopoiesis | 11 | 2015 | 194 | 0.520 |
Why?
|
| Reactive Oxygen Species | 7 | 2020 | 621 | 0.510 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 4 | 2019 | 17 | 0.500 |
Why?
|
| Mitochondrial Proteins | 2 | 2018 | 262 | 0.490 |
Why?
|
| Mutation | 10 | 2026 | 4089 | 0.490 |
Why?
|
| Triterpenes | 2 | 2014 | 25 | 0.480 |
Why?
|
| Energy Metabolism | 5 | 2021 | 935 | 0.470 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 8 | 2022 | 49 | 0.470 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2016 | 95 | 0.460 |
Why?
|
| Homeostasis | 2 | 2021 | 640 | 0.460 |
Why?
|
| Cells, Cultured | 15 | 2019 | 4154 | 0.460 |
Why?
|
| Mice, Inbred C57BL | 23 | 2021 | 5992 | 0.450 |
Why?
|
| Liver | 7 | 2020 | 1887 | 0.450 |
Why?
|
| Sirolimus | 5 | 2016 | 281 | 0.450 |
Why?
|
| Membrane Proteins | 6 | 2024 | 1166 | 0.450 |
Why?
|
| Xenograft Model Antitumor Assays | 15 | 2020 | 928 | 0.440 |
Why?
|
| Oxidation-Reduction | 6 | 2019 | 1087 | 0.430 |
Why?
|
| Neoplasms | 7 | 2015 | 2875 | 0.430 |
Why?
|
| Multiple Myeloma | 3 | 2024 | 291 | 0.420 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2025 | 449 | 0.410 |
Why?
|
| Benzofurans | 1 | 2014 | 26 | 0.410 |
Why?
|
| Thiadiazoles | 3 | 2011 | 27 | 0.410 |
Why?
|
| Interferon Regulatory Factors | 3 | 2024 | 44 | 0.410 |
Why?
|
| Dioxolanes | 1 | 2013 | 6 | 0.410 |
Why?
|
| Phosphoproteins | 3 | 2020 | 344 | 0.400 |
Why?
|
| Transduction, Genetic | 7 | 2006 | 133 | 0.400 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2014 | 69 | 0.390 |
Why?
|
| Bone Marrow Cells | 12 | 2024 | 320 | 0.390 |
Why?
|
| Glucose | 1 | 2018 | 1047 | 0.390 |
Why?
|
| Enzyme Inhibitors | 5 | 2010 | 824 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 8 | 2020 | 1519 | 0.370 |
Why?
|
| Oxidative Stress | 4 | 2014 | 1339 | 0.360 |
Why?
|
| Bone Marrow | 7 | 2024 | 304 | 0.360 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 570 | 0.360 |
Why?
|
| Cell Differentiation | 16 | 2022 | 2050 | 0.360 |
Why?
|
| Tumor Microenvironment | 5 | 2025 | 732 | 0.360 |
Why?
|
| Cell Death | 8 | 2012 | 383 | 0.350 |
Why?
|
| Oncogenes | 1 | 2012 | 119 | 0.350 |
Why?
|
| Adipose Tissue | 1 | 2016 | 652 | 0.350 |
Why?
|
| Antigens, CD | 8 | 2010 | 555 | 0.350 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 73 | 0.350 |
Why?
|
| Adenoviridae | 3 | 2001 | 199 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2025 | 1137 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2021 | 623 | 0.330 |
Why?
|
| Neoplasm, Residual | 4 | 2024 | 139 | 0.330 |
Why?
|
| Glycolysis | 2 | 2025 | 339 | 0.320 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 177 | 0.320 |
Why?
|
| Gene Transfer Techniques | 4 | 2001 | 185 | 0.310 |
Why?
|
| Insulin Resistance | 1 | 2018 | 1241 | 0.310 |
Why?
|
| Leukemia, Experimental | 2 | 2006 | 27 | 0.300 |
Why?
|
| RNA Splicing Factors | 2 | 2020 | 64 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2022 | 675 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2013 | 210 | 0.300 |
Why?
|
| Models, Biological | 7 | 2011 | 1821 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2009 | 55 | 0.290 |
Why?
|
| Structure-Activity Relationship | 9 | 2021 | 570 | 0.290 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2008 | 11 | 0.280 |
Why?
|
| Transcriptome | 6 | 2024 | 1045 | 0.280 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 380 | 0.280 |
Why?
|
| Hematologic Neoplasms | 3 | 2017 | 161 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 2027 | 0.280 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 4557 | 0.280 |
Why?
|
| Drug Screening Assays, Antitumor | 9 | 2021 | 191 | 0.270 |
Why?
|
| Immunophenotyping | 8 | 2016 | 322 | 0.270 |
Why?
|
| Neoplasm Transplantation | 6 | 2016 | 251 | 0.270 |
Why?
|
| Female | 43 | 2025 | 78271 | 0.260 |
Why?
|
| Indoles | 3 | 2017 | 501 | 0.260 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2025 | 75 | 0.260 |
Why?
|
| Cell Lineage | 6 | 2012 | 376 | 0.260 |
Why?
|
| Genetic Vectors | 5 | 2001 | 337 | 0.250 |
Why?
|
| Stem Cell Transplantation | 2 | 2005 | 191 | 0.250 |
Why?
|
| Hematopoietic System | 1 | 2006 | 7 | 0.250 |
Why?
|
| Prognosis | 9 | 2025 | 4282 | 0.240 |
Why?
|
| Drug Design | 4 | 2016 | 173 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2014 | 529 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2024 | 1455 | 0.240 |
Why?
|
| Tanacetum parthenium | 1 | 2005 | 1 | 0.230 |
Why?
|
| Tumor Burden | 3 | 2016 | 319 | 0.230 |
Why?
|
| Software | 2 | 2025 | 690 | 0.230 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 40 | 0.230 |
Why?
|
| NAD | 1 | 2026 | 81 | 0.230 |
Why?
|
| Myeloid Cells | 1 | 2006 | 148 | 0.230 |
Why?
|
| Programming Languages | 1 | 2025 | 25 | 0.230 |
Why?
|
| Cell Cycle | 5 | 2021 | 596 | 0.220 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 2182 | 0.220 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 358 | 0.220 |
Why?
|
| Taurine | 1 | 2025 | 41 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2026 | 253 | 0.220 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2024 | 14 | 0.210 |
Why?
|
| Ikaros Transcription Factor | 1 | 2024 | 23 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 983 | 0.210 |
Why?
|
| Histiocytic Sarcoma | 1 | 2024 | 3 | 0.210 |
Why?
|
| Information Storage and Retrieval | 1 | 2025 | 121 | 0.210 |
Why?
|
| Thalidomide | 1 | 2024 | 43 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 432 | 0.210 |
Why?
|
| Hemangiosarcoma | 1 | 2024 | 23 | 0.200 |
Why?
|
| Disease Progression | 6 | 2025 | 2847 | 0.200 |
Why?
|
| Carcinogenesis | 1 | 2025 | 229 | 0.190 |
Why?
|
| Acute Disease | 6 | 2005 | 1030 | 0.190 |
Why?
|
| Retroviridae | 6 | 2006 | 101 | 0.190 |
Why?
|
| Nuclear Proteins | 4 | 2024 | 748 | 0.190 |
Why?
|
| Pyrroles | 2 | 2015 | 217 | 0.190 |
Why?
|
| Male | 35 | 2025 | 72315 | 0.190 |
Why?
|
| Drug Discovery | 3 | 2013 | 155 | 0.190 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 8265 | 0.180 |
Why?
|
| Pyrimidines | 2 | 2017 | 532 | 0.180 |
Why?
|
| Spliceosomes | 2 | 2020 | 52 | 0.180 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2019 | 26 | 0.180 |
Why?
|
| Protein Biosynthesis | 2 | 2025 | 458 | 0.180 |
Why?
|
| Osteoblasts | 4 | 2012 | 145 | 0.180 |
Why?
|
| Interleukin-1 | 1 | 2025 | 961 | 0.180 |
Why?
|
| Niacinamide | 2 | 2020 | 86 | 0.180 |
Why?
|
| Drug Synergism | 5 | 2020 | 357 | 0.170 |
Why?
|
| Aged | 13 | 2025 | 25913 | 0.170 |
Why?
|
| Transplantation, Heterologous | 3 | 2010 | 193 | 0.170 |
Why?
|
| Benzothiazoles | 3 | 2022 | 40 | 0.170 |
Why?
|
| c-Mer Tyrosine Kinase | 2 | 2018 | 38 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 202 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2022 | 69 | 0.170 |
Why?
|
| Leukocytes | 1 | 2002 | 295 | 0.170 |
Why?
|
| Trans-Activators | 2 | 2021 | 405 | 0.170 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 83 | 0.170 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2000 | 5 | 0.170 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 13 | 0.170 |
Why?
|
| Bone Marrow Diseases | 1 | 2020 | 20 | 0.160 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 1313 | 0.160 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2001 | 168 | 0.160 |
Why?
|
| Mice, Knockout | 7 | 2016 | 3121 | 0.160 |
Why?
|
| Recurrence | 6 | 2025 | 1135 | 0.160 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2020 | 48 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2020 | 56 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2002 | 194 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 917 | 0.160 |
Why?
|
| Cell Separation | 5 | 2011 | 307 | 0.160 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 2452 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 264 | 0.160 |
Why?
|
| Membrane Glycoproteins | 6 | 2025 | 496 | 0.160 |
Why?
|
| Molecular Structure | 6 | 2018 | 499 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2020 | 437 | 0.150 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 172 | 0.150 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2015 | 192 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2015 | 230 | 0.150 |
Why?
|
| Cell-Derived Microparticles | 1 | 2020 | 75 | 0.150 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2016 | 162 | 0.150 |
Why?
|
| Splicing Factor U2AF | 1 | 2019 | 18 | 0.150 |
Why?
|
| Inflammation | 3 | 2021 | 2878 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 3 | 2016 | 294 | 0.150 |
Why?
|
| Tricarboxylic Acids | 1 | 2018 | 11 | 0.150 |
Why?
|
| Infertility | 1 | 1999 | 55 | 0.150 |
Why?
|
| Blotting, Western | 5 | 2015 | 1187 | 0.140 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 210 | 0.140 |
Why?
|
| Ketoglutaric Acids | 1 | 2018 | 23 | 0.140 |
Why?
|
| HEK293 Cells | 2 | 2019 | 744 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 205 | 0.140 |
Why?
|
| Glutamine | 1 | 2019 | 109 | 0.140 |
Why?
|
| Gender Identity | 1 | 1999 | 121 | 0.140 |
Why?
|
| Genes | 1 | 1998 | 226 | 0.140 |
Why?
|
| Cytoprotection | 2 | 2016 | 55 | 0.140 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 265 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2014 | 139 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 758 | 0.140 |
Why?
|
| Cytokines | 7 | 2020 | 2061 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2019 | 162 | 0.140 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2016 | 72 | 0.140 |
Why?
|
| RNA Interference | 3 | 2015 | 476 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 2021 | 453 | 0.130 |
Why?
|
| Gene Expression | 5 | 2020 | 1490 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2008 | 76 | 0.130 |
Why?
|
| Arthritis, Experimental | 1 | 2019 | 141 | 0.130 |
Why?
|
| Phosphorylation | 5 | 2022 | 1732 | 0.130 |
Why?
|
| Biological Transport | 1 | 2018 | 417 | 0.130 |
Why?
|
| Succinates | 1 | 2017 | 24 | 0.130 |
Why?
|
| Recombinational DNA Repair | 1 | 2017 | 19 | 0.130 |
Why?
|
| Carboxylic Acids | 1 | 2017 | 34 | 0.130 |
Why?
|
| Boronic Acids | 3 | 2013 | 37 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 1047 | 0.130 |
Why?
|
| RNA, Messenger | 10 | 2011 | 2832 | 0.130 |
Why?
|
| Proteasome Inhibitors | 2 | 2020 | 40 | 0.130 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 261 | 0.130 |
Why?
|
| Triazoles | 1 | 2018 | 184 | 0.130 |
Why?
|
| Phenotype | 4 | 2019 | 3162 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 1053 | 0.130 |
Why?
|
| Esters | 1 | 2017 | 78 | 0.120 |
Why?
|
| Phthalazines | 1 | 2017 | 64 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2015 | 681 | 0.120 |
Why?
|
| Phenylacetates | 1 | 2016 | 10 | 0.120 |
Why?
|
| Amides | 1 | 2017 | 101 | 0.120 |
Why?
|
| NADP | 1 | 2016 | 55 | 0.120 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 26 | 0.120 |
Why?
|
| Sulfhydryl Compounds | 2 | 2009 | 189 | 0.120 |
Why?
|
| Immunity, Innate | 2 | 2021 | 846 | 0.120 |
Why?
|
| CD36 Antigens | 1 | 2016 | 32 | 0.120 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 498 | 0.120 |
Why?
|
| Gonads | 1 | 2016 | 23 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 527 | 0.120 |
Why?
|
| Students, Medical | 1 | 2021 | 375 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 264 | 0.120 |
Why?
|
| Pyrazines | 3 | 2013 | 92 | 0.120 |
Why?
|
| Deoxyglucose | 1 | 2016 | 51 | 0.120 |
Why?
|
| Lipolysis | 1 | 2016 | 46 | 0.120 |
Why?
|
| Genome, Human | 1 | 2018 | 422 | 0.120 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2016 | 69 | 0.120 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2015 | 5 | 0.120 |
Why?
|
| Neoplasms, Experimental | 2 | 2016 | 173 | 0.120 |
Why?
|
| Cell Division | 5 | 2004 | 766 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2015 | 32 | 0.120 |
Why?
|
| Camptothecin | 1 | 2016 | 140 | 0.120 |
Why?
|
| Genomics | 2 | 2018 | 834 | 0.120 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 61 | 0.120 |
Why?
|
| Transplantation, Homologous | 4 | 2010 | 415 | 0.120 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2008 | 50 | 0.120 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1995 | 33 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2016 | 851 | 0.110 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 1499 | 0.110 |
Why?
|
| Transcription Factors | 5 | 2022 | 1741 | 0.110 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 14 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 337 | 0.110 |
Why?
|
| Methyltransferases | 1 | 2016 | 74 | 0.110 |
Why?
|
| Cell Membrane | 3 | 2009 | 706 | 0.110 |
Why?
|
| Lactones | 3 | 2021 | 58 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2015 | 47 | 0.110 |
Why?
|
| Molecular Docking Simulation | 3 | 2021 | 124 | 0.110 |
Why?
|
| Oligomycins | 1 | 2014 | 7 | 0.110 |
Why?
|
| Doxycycline | 1 | 2015 | 62 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2014 | 220 | 0.110 |
Why?
|
| Metabolome | 1 | 2018 | 384 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 463 | 0.110 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 23 | 0.110 |
Why?
|
| Homeodomain Proteins | 5 | 2016 | 523 | 0.110 |
Why?
|
| Transcription Factor RelA | 2 | 2021 | 85 | 0.110 |
Why?
|
| Remission Induction | 4 | 2019 | 307 | 0.110 |
Why?
|
| Piperazines | 1 | 2017 | 381 | 0.110 |
Why?
|
| Eukaryotic Initiation Factor-4E | 2 | 2005 | 32 | 0.110 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 25 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2014 | 18 | 0.110 |
Why?
|
| Dogs | 2 | 2024 | 437 | 0.110 |
Why?
|
| Phenylbutyrates | 1 | 2014 | 23 | 0.110 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 105 | 0.110 |
Why?
|
| I-kappa B Kinase | 1 | 2014 | 51 | 0.110 |
Why?
|
| Osteoclasts | 2 | 2011 | 52 | 0.110 |
Why?
|
| Necrosis | 1 | 2015 | 244 | 0.100 |
Why?
|
| Computational Biology | 1 | 2019 | 680 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 141 | 0.100 |
Why?
|
| Selenium | 1 | 2014 | 49 | 0.100 |
Why?
|
| Eicosanoids | 1 | 2014 | 58 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 172 | 0.100 |
Why?
|
| Piperidones | 1 | 2013 | 1 | 0.100 |
Why?
|
| Thiamine | 1 | 2014 | 18 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 1999 | 717 | 0.100 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2013 | 20 | 0.100 |
Why?
|
| Glutathione Peroxidase | 1 | 2013 | 39 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 62 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 321 | 0.100 |
Why?
|
| Integrin beta3 | 1 | 2013 | 14 | 0.100 |
Why?
|
| Hydrolases | 1 | 2014 | 55 | 0.100 |
Why?
|
| Biomarkers | 2 | 2019 | 4271 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2024 | 11679 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2017 | 509 | 0.100 |
Why?
|
| Middle Aged | 13 | 2025 | 35875 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 197 | 0.100 |
Why?
|
| Tyrphostins | 1 | 2012 | 18 | 0.090 |
Why?
|
| Phenylurea Compounds | 3 | 2022 | 112 | 0.090 |
Why?
|
| Leupeptins | 2 | 2002 | 12 | 0.090 |
Why?
|
| Serpins | 1 | 2012 | 28 | 0.090 |
Why?
|
| Cytomegalovirus | 2 | 2004 | 168 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2015 | 737 | 0.090 |
Why?
|
| Mice, Inbred Strains | 3 | 2006 | 397 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 149 | 0.090 |
Why?
|
| Receptors, Immunologic | 3 | 2009 | 206 | 0.090 |
Why?
|
| Base Sequence | 7 | 2013 | 2190 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 2089 | 0.090 |
Why?
|
| Spleen | 3 | 2011 | 508 | 0.090 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2011 | 9 | 0.090 |
Why?
|
| Chemokine CCL3 | 1 | 2011 | 26 | 0.090 |
Why?
|
| Pyridones | 1 | 2013 | 199 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2015 | 34 | 0.090 |
Why?
|
| Cellular Microenvironment | 1 | 2012 | 94 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 573 | 0.080 |
Why?
|
| Protein Domains | 2 | 2024 | 313 | 0.080 |
Why?
|
| ADP-ribosyl Cyclase 1 | 4 | 2009 | 43 | 0.080 |
Why?
|
| Prodrugs | 1 | 2011 | 52 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 102 | 0.080 |
Why?
|
| Seminal Vesicles | 1 | 2010 | 9 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2002 | 94 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 675 | 0.080 |
Why?
|
| Adult | 12 | 2025 | 40449 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 1999 | 1152 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2015 | 539 | 0.080 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 89 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 6 | 2024 | 1054 | 0.080 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2010 | 10 | 0.080 |
Why?
|
| Genetic Markers | 3 | 1999 | 331 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 1 | 2010 | 8 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2010 | 194 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 846 | 0.080 |
Why?
|
| Binding Sites | 3 | 2021 | 1329 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 4 | 2009 | 95 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 1169 | 0.080 |
Why?
|
| I-kappa B Proteins | 2 | 2017 | 74 | 0.080 |
Why?
|
| Retrospective Studies | 7 | 2024 | 17066 | 0.080 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2010 | 65 | 0.080 |
Why?
|
| Ethanol | 1 | 2015 | 627 | 0.080 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 102 | 0.080 |
Why?
|
| Receptors, Cell Surface | 3 | 2022 | 377 | 0.080 |
Why?
|
| Neutrophils | 1 | 2015 | 1134 | 0.080 |
Why?
|
| K562 Cells | 2 | 2020 | 93 | 0.080 |
Why?
|
| Prostate | 1 | 2010 | 158 | 0.070 |
Why?
|
| Idarubicin | 2 | 2013 | 5 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 2007 | 252 | 0.070 |
Why?
|
| Vidarabine | 1 | 2008 | 32 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2009 | 178 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 704 | 0.070 |
Why?
|
| Radiation Oncology | 1 | 2009 | 88 | 0.070 |
Why?
|
| Coculture Techniques | 2 | 2006 | 246 | 0.070 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 635 | 0.070 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2008 | 12 | 0.070 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2008 | 12 | 0.070 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2008 | 13 | 0.070 |
Why?
|
| Machine Learning | 2 | 2025 | 585 | 0.070 |
Why?
|
| Rats | 5 | 2015 | 5597 | 0.070 |
Why?
|
| RNA Splicing | 2 | 2020 | 284 | 0.070 |
Why?
|
| Lymphocytes | 3 | 1999 | 382 | 0.070 |
Why?
|
| Terpenes | 1 | 2008 | 25 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 1995 | 823 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5408 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2021 | 87 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2015 | 682 | 0.070 |
Why?
|
| DNA Mismatch Repair | 1 | 2008 | 52 | 0.070 |
Why?
|
| Primary Cell Culture | 2 | 2020 | 173 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 2013 | 2930 | 0.070 |
Why?
|
| Genetic Therapy | 2 | 2000 | 313 | 0.070 |
Why?
|
| ADP-ribosyl Cyclase | 3 | 2004 | 6 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2006 | 72 | 0.070 |
Why?
|
| Insulin | 1 | 2018 | 2507 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2008 | 177 | 0.060 |
Why?
|
| Biological Availability | 1 | 2007 | 142 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 701 | 0.060 |
Why?
|
| Bortezomib | 3 | 2013 | 55 | 0.060 |
Why?
|
| Aldehydes | 1 | 2008 | 142 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 1253 | 0.060 |
Why?
|
| Clone Cells | 3 | 2001 | 266 | 0.060 |
Why?
|
| Receptors, LDL | 1 | 2007 | 53 | 0.060 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 89 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2008 | 248 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2007 | 98 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 140 | 0.060 |
Why?
|
| Receptors, Virus | 2 | 1997 | 96 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 462 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2008 | 159 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 171 | 0.060 |
Why?
|
| Interleukin-1 Receptor Accessory Protein | 1 | 2025 | 9 | 0.060 |
Why?
|
| Exome | 2 | 2018 | 227 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2010 | 710 | 0.060 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2025 | 25 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 415 | 0.060 |
Why?
|
| Asparagine | 1 | 2025 | 35 | 0.060 |
Why?
|
| Plants, Medicinal | 1 | 2005 | 23 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2006 | 112 | 0.060 |
Why?
|
| Receptors, Notch | 1 | 2006 | 92 | 0.060 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 2 | 2016 | 11 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2008 | 536 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2014 | 433 | 0.060 |
Why?
|
| Cardiolipins | 1 | 2025 | 82 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2018 | 389 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 1496 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2022 | 5960 | 0.060 |
Why?
|
| Graft Survival | 2 | 2009 | 526 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 427 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2006 | 219 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2015 | 47 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1406 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2005 | 153 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2004 | 65 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 381 | 0.050 |
Why?
|
| Reference Values | 2 | 2007 | 797 | 0.050 |
Why?
|
| Arsenicals | 2 | 2017 | 28 | 0.050 |
Why?
|
| Oxides | 2 | 2017 | 51 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 2 | 2001 | 3 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2004 | 79 | 0.050 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 70 | 0.050 |
Why?
|
| Protein Binding | 3 | 2020 | 2273 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2024 | 93 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2025 | 154 | 0.050 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 509 | 0.050 |
Why?
|
| Stereoisomerism | 2 | 2016 | 104 | 0.050 |
Why?
|
| Antigens, Differentiation | 2 | 2001 | 77 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2004 | 115 | 0.050 |
Why?
|
| Forecasting | 1 | 2005 | 391 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 212 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2010 | 766 | 0.050 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2022 | 21 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2007 | 409 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 67 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 73 | 0.050 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2002 | 25 | 0.050 |
Why?
|
| Monocytes | 3 | 2018 | 538 | 0.050 |
Why?
|
| Lentivirus | 2 | 2019 | 60 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 111 | 0.050 |
Why?
|
| Virus Latency | 1 | 2002 | 90 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 206 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 42 | 0.040 |
Why?
|
| Biopsy | 2 | 2015 | 1075 | 0.040 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2002 | 36 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 117 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2115 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2002 | 75 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2001 | 17 | 0.040 |
Why?
|
| Young Adult | 4 | 2021 | 14105 | 0.040 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2001 | 10 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2001 | 88 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2012 | 341 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2018 | 1618 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 150 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2020 | 34 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 769 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2001 | 223 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2001 | 186 | 0.040 |
Why?
|
| DNA Primers | 2 | 2002 | 512 | 0.040 |
Why?
|
| Virus Diseases | 2 | 2000 | 216 | 0.040 |
Why?
|
| Mice, Inbred C3H | 2 | 1990 | 251 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 80 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 153 | 0.040 |
Why?
|
| DNA | 4 | 2008 | 1463 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1999 | 27 | 0.040 |
Why?
|
| Cell Line | 4 | 1999 | 2882 | 0.040 |
Why?
|
| Alleles | 1 | 2002 | 879 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2024 | 1025 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 2011 | 247 | 0.040 |
Why?
|
| Radiation Chimera | 2 | 2008 | 27 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2018 | 1129 | 0.040 |
Why?
|
| Actins | 1 | 2001 | 425 | 0.040 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2019 | 22 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2021 | 426 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 50 | 0.040 |
Why?
|
| Infection Control | 1 | 2000 | 172 | 0.040 |
Why?
|
| Protein Transport | 1 | 2020 | 441 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2018 | 30 | 0.040 |
Why?
|
| Macrophages | 2 | 2018 | 1511 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 37 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2018 | 122 | 0.030 |
Why?
|
| Stromal Cells | 2 | 2012 | 124 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 29 | 0.030 |
Why?
|
| Proteomics | 1 | 2024 | 1195 | 0.030 |
Why?
|
| Cell Movement | 1 | 2001 | 965 | 0.030 |
Why?
|
| Phosphate Transport Proteins | 1 | 1996 | 2 | 0.030 |
Why?
|
| Interphase | 1 | 1996 | 38 | 0.030 |
Why?
|
| Adenovirus Infections, Human | 1 | 1996 | 15 | 0.030 |
Why?
|
| Bacillus megaterium | 1 | 2016 | 1 | 0.030 |
Why?
|
| NADPH-Ferrihemoprotein Reductase | 1 | 2016 | 10 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 143 | 0.030 |
Why?
|
| Hydrazines | 1 | 2016 | 37 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 478 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 126 | 0.030 |
Why?
|
| Acylation | 1 | 2016 | 30 | 0.030 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2016 | 24 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 266 | 0.030 |
Why?
|
| Kinetics | 3 | 2011 | 1627 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2014 | 650 | 0.030 |
Why?
|
| Symporters | 1 | 1996 | 48 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 442 | 0.030 |
Why?
|
| Gliosarcoma | 1 | 2015 | 8 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3671 | 0.030 |
Why?
|
| Transfection | 1 | 1998 | 940 | 0.030 |
Why?
|
| COP9 Signalosome Complex | 1 | 2015 | 5 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 80 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2015 | 14 | 0.030 |
Why?
|
| Dimerization | 1 | 2015 | 194 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 863 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2015 | 10 | 0.030 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
|
| Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 162 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 2005 | 2155 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2014 | 77 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 627 | 0.030 |
Why?
|
| Ionomycin | 1 | 2014 | 22 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2017 | 862 | 0.030 |
Why?
|
| Lethal Dose 50 | 1 | 2014 | 15 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 322 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2014 | 14 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 406 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2014 | 26 | 0.030 |
Why?
|
| DNA Damage | 1 | 2017 | 430 | 0.030 |
Why?
|
| Cyclin D1 | 2 | 2005 | 61 | 0.030 |
Why?
|
| Amino Acids, Aromatic | 1 | 2014 | 7 | 0.030 |
Why?
|
| Superoxides | 1 | 2014 | 204 | 0.030 |
Why?
|
| Arachidonic Acids | 1 | 2014 | 43 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 124 | 0.030 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2013 | 9 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1996 | 342 | 0.030 |
Why?
|
| Dyspnea | 1 | 2016 | 251 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2005 | 121 | 0.030 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2014 | 39 | 0.030 |
Why?
|
| Ribavirin | 1 | 2014 | 80 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2013 | 42 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1999 | 790 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 653 | 0.030 |
Why?
|
| Serine | 1 | 2014 | 145 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 135 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 905 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2013 | 69 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2013 | 96 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 366 | 0.020 |
Why?
|
| Caspases | 1 | 2014 | 232 | 0.020 |
Why?
|
| Transplant Recipients | 1 | 2015 | 180 | 0.020 |
Why?
|
| Fetus | 2 | 1995 | 803 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1382 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2005 | 396 | 0.020 |
Why?
|
| Child | 4 | 2020 | 22633 | 0.020 |
Why?
|
| HIV-1 | 1 | 1999 | 896 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1694 | 0.020 |
Why?
|
| Transcription Factor RelB | 1 | 2012 | 3 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 139 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 1992 | 45 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 459 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 549 | 0.020 |
Why?
|
| Time Factors | 4 | 2004 | 7173 | 0.020 |
Why?
|
| Cell Size | 1 | 2012 | 92 | 0.020 |
Why?
|
| Urban Population | 1 | 2015 | 491 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1991 | 29 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 2363 | 0.020 |
Why?
|
| Farnesyltranstransferase | 1 | 2011 | 21 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 2608 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2011 | 47 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2015 | 540 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 21 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2016 | 854 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1992 | 126 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 779 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 320 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 88 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2013 | 397 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 200 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 1795 | 0.020 |
Why?
|
| Infant | 3 | 2015 | 10034 | 0.020 |
Why?
|
| Diphosphonates | 1 | 2011 | 68 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2011 | 80 | 0.020 |
Why?
|
| beta Catenin | 1 | 2013 | 252 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 10779 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1991 | 273 | 0.020 |
Why?
|
| Adolescent | 3 | 2019 | 22428 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 81 | 0.020 |
Why?
|
| Receptors, Fibronectin | 1 | 1990 | 6 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1266 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1990 | 85 | 0.020 |
Why?
|
| Virus Replication | 2 | 2004 | 529 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 1990 | 17 | 0.020 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2010 | 40 | 0.020 |
Why?
|
| Imidazoles | 1 | 2011 | 254 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2010 | 64 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1990 | 157 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2009 | 30 | 0.020 |
Why?
|
| Galactosyltransferases | 1 | 1989 | 12 | 0.020 |
Why?
|
| Fibronectins | 1 | 1990 | 136 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 955 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 21 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 103 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2009 | 120 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1462 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 851 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 2009 | 60 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2009 | 109 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2008 | 40 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 242 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1990 | 455 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2009 | 81 | 0.020 |
Why?
|
| Genes, abl | 1 | 2008 | 4 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 254 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2008 | 13 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2015 | 11787 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1989 | 91 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2008 | 10 | 0.020 |
Why?
|
| Lymphoma | 1 | 2009 | 232 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2007 | 21 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2008 | 206 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2008 | 100 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2009 | 269 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1989 | 508 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 492 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1886 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1989 | 355 | 0.020 |
Why?
|
| Granulocytes | 2 | 1999 | 80 | 0.020 |
Why?
|
| Group V Phospholipases A2 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1837 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2007 | 79 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2009 | 223 | 0.020 |
Why?
|
| Pyridines | 1 | 2011 | 605 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2008 | 221 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2009 | 314 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 1098 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 592 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2006 | 27 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2006 | 22 | 0.020 |
Why?
|
| Adenylyl Cyclases | 1 | 2006 | 60 | 0.010 |
Why?
|
| Antioxidants | 1 | 2009 | 549 | 0.010 |
Why?
|
| Water | 1 | 2009 | 469 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2007 | 169 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 125 | 0.010 |
Why?
|
| Ornithine Decarboxylase | 1 | 2005 | 13 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 684 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 467 | 0.010 |
Why?
|
| Hospitalization | 1 | 2015 | 2433 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 1907 | 0.010 |
Why?
|
| Aging | 1 | 1995 | 1966 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 269 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 310 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 673 | 0.010 |
Why?
|
| Genes, myc | 1 | 2003 | 50 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2016 | 7990 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 276 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 163 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 1257 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2002 | 43 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 87 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 275 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1047 | 0.010 |
Why?
|
| Pregnancy | 2 | 1997 | 7190 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2002 | 366 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1985 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 185 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 618 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 375 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 405 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2004 | 424 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2002 | 358 | 0.010 |
Why?
|
| CD24 Antigen | 1 | 1999 | 18 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 1999 | 17 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1999 | 27 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2000 | 203 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1999 | 89 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1999 | 76 | 0.010 |
Why?
|
| Leukemia Virus, Murine | 1 | 1999 | 17 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 1999 | 73 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2000 | 221 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1999 | 191 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1217 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2002 | 688 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2000 | 267 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1998 | 19 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1998 | 79 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1998 | 145 | 0.010 |
Why?
|
| Transgenes | 1 | 1998 | 189 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 1997 | 15 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 161 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2002 | 1034 | 0.010 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins | 1 | 1996 | 10 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1997 | 156 | 0.010 |
Why?
|
| HIV Infections | 1 | 1992 | 3154 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 1998 | 499 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 876 | 0.010 |
Why?
|
| Antibodies | 1 | 1994 | 401 | 0.010 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1992 | 42 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1992 | 34 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1993 | 284 | 0.010 |
Why?
|
| Muridae | 1 | 1991 | 6 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1992 | 316 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 157 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1991 | 124 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1991 | 204 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1999 | 1982 | 0.010 |
Why?
|
| Multigene Family | 1 | 1991 | 204 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 510 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1991 | 540 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1991 | 311 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1992 | 246 | 0.000 |
Why?
|
| Receptors, Laminin | 1 | 1989 | 2 | 0.000 |
Why?
|
| Galactose | 1 | 1989 | 34 | 0.000 |
Why?
|
| Laminin | 1 | 1989 | 72 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1989 | 327 | 0.000 |
Why?
|
| Glycosylation | 1 | 1989 | 172 | 0.000 |
Why?
|
| Immunoblotting | 1 | 1989 | 300 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1992 | 2029 | 0.000 |
Why?
|
| Incidence | 1 | 1992 | 2879 | 0.000 |
Why?
|
| United States | 1 | 2000 | 15966 | 0.000 |
Why?
|